371 related articles for article (PubMed ID: 20030568)
1. Combined oral prolonged-release oxycodone and naloxone in opioid-induced bowel dysfunction: review of efficacy and safety data in the treatment of patients experiencing chronic pain.
Clemens KE; Mikus G
Expert Opin Pharmacother; 2010 Feb; 11(2):297-310. PubMed ID: 20030568
[TBL] [Abstract][Full Text] [Related]
2. Analgesic efficacy and safety of oxycodone in combination with naloxone as prolonged release tablets in patients with moderate to severe chronic pain.
Vondrackova D; Leyendecker P; Meissner W; Hopp M; Szombati I; Hermanns K; Ruckes C; Weber S; Grothe B; Fleischer W; Reimer K
J Pain; 2008 Dec; 9(12):1144-54. PubMed ID: 18708300
[TBL] [Abstract][Full Text] [Related]
3. A randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation.
Meissner W; Leyendecker P; Mueller-Lissner S; Nadstawek J; Hopp M; Ruckes C; Wirz S; Fleischer W; Reimer K
Eur J Pain; 2009 Jan; 13(1):56-64. PubMed ID: 18762438
[TBL] [Abstract][Full Text] [Related]
4. Prolonged-release oxycodone/naloxone in nonmalignant pain: single-center study in patients with constipation.
Gatti A; Casali M; Lazzari M; Tufaro G; Gafforio P; Silvestri C; Marcassa C; Sabato AF
Adv Ther; 2013 Jan; 30(1):41-59. PubMed ID: 23269562
[TBL] [Abstract][Full Text] [Related]
5. Meeting the challenges of opioid-induced constipation in chronic pain management - a novel approach.
Reimer K; Hopp M; Zenz M; Maier C; Holzer P; Mikus G; Bosse B; Smith K; Buschmann-Kramm C; Leyendecker P
Pharmacology; 2009; 83(1):10-7. PubMed ID: 18957874
[TBL] [Abstract][Full Text] [Related]
6. Prolonged-release oxycodone/naloxone in the treatment of neuropathic pain - results from a large observational study.
Hermanns K; Junker U; Nolte T
Expert Opin Pharmacother; 2012 Feb; 13(3):299-311. PubMed ID: 22224497
[TBL] [Abstract][Full Text] [Related]
7. Innovative pain therapy with a fixed combination of prolonged-release oxycodone/naloxone: a large observational study under conditions of daily practice.
Schutter U; Grunert S; Meyer C; Schmidt T; Nolte T
Curr Med Res Opin; 2010 Jun; 26(6):1377-87. PubMed ID: 20380506
[TBL] [Abstract][Full Text] [Related]
8. Oxycodone/naloxone in the management of patients with pain and opioid-induced bowel dysfunction.
Leppert W
Curr Drug Targets; 2014 Jan; 15(1):124-35. PubMed ID: 24020972
[TBL] [Abstract][Full Text] [Related]
9. Quality of life and healthcare resource in patients receiving opioids for chronic pain: a review of the place of oxycodone/naloxone.
Morlion B; Clemens KE; Dunlop W
Clin Drug Investig; 2015 Jan; 35(1):1-11. PubMed ID: 25479959
[TBL] [Abstract][Full Text] [Related]
10. Mu-opioid antagonists for opioid-induced bowel dysfunction in people with cancer and people receiving palliative care.
Candy B; Jones L; Vickerstaff V; Larkin PJ; Stone P
Cochrane Database Syst Rev; 2018 Jun; 6(6):CD006332. PubMed ID: 29869799
[TBL] [Abstract][Full Text] [Related]
11. The attractiveness of opposites: agonists and antagonists.
O'Brien T
J Pain Palliat Care Pharmacother; 2015 Mar; 29(1):67-9. PubMed ID: 25643224
[TBL] [Abstract][Full Text] [Related]
12. Fixed-ratio combination oxycodone/naloxone compared with oxycodone alone for the relief of opioid-induced constipation in moderate-to-severe noncancer pain.
Simpson K; Leyendecker P; Hopp M; Müller-Lissner S; Löwenstein O; De Andrés J; Troy Ferrarons J; Bosse B; Krain B; Nichols T; Kremers W; Reimer K
Curr Med Res Opin; 2008 Dec; 24(12):3503-12. PubMed ID: 19032132
[TBL] [Abstract][Full Text] [Related]
13. The role of opioid receptor antagonists in the treatment of opioid-induced constipation: a review.
Leppert W
Adv Ther; 2010 Oct; 27(10):714-30. PubMed ID: 20799006
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of moderate/severe chronic non-malignant pain: results of a prospectively designed pooled analysis of two randomised, double-blind clinical trials.
Löwenstein O; Leyendecker P; Lux EA; Blagden M; Simpson KH; Hopp M; Bosse B; Reimer K
BMC Clin Pharmacol; 2010 Sep; 10():12. PubMed ID: 20920236
[TBL] [Abstract][Full Text] [Related]
15. The role of oxycodone/naloxone in the management of patients with pain and opioid-induced constipation.
Leppert W; Zajaczkowska R; Wordliczek J
Expert Opin Pharmacother; 2019 Apr; 20(5):511-522. PubMed ID: 30625013
[TBL] [Abstract][Full Text] [Related]
16. Oxycodone combined with opioid receptor antagonists: efficacy and safety.
Davis M; Goforth HW; Gamier P
Expert Opin Drug Saf; 2013 May; 12(3):389-402. PubMed ID: 23534906
[TBL] [Abstract][Full Text] [Related]
17. Developments in managing severe chronic pain: role of oxycodone-naloxone extended release.
Fanelli G; Fanelli A
Drug Des Devel Ther; 2015; 9():3811-6. PubMed ID: 26229442
[TBL] [Abstract][Full Text] [Related]
18. Long-term efficacy and safety of oxycodone-naloxone prolonged-release formulation (up to 180/90 mg daily) - results of the open-label extension phase of a phase III multicenter, multiple-dose, randomized, controlled study.
Dupoiron D; Stachowiak A; Loewenstein O; Ellery A; Kremers W; Bosse B; Hopp M
Eur J Pain; 2017 Oct; 21(9):1485-1494. PubMed ID: 28474460
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and tolerability of oral oxycodone and oxycodone/naloxone combination in opioid-naïve cancer patients: a propensity analysis.
Lazzari M; Greco MT; Marcassa C; Finocchi S; Caldarulo C; Corli O
Drug Des Devel Ther; 2015; 9():5863-72. PubMed ID: 26586937
[TBL] [Abstract][Full Text] [Related]
20. Long-term efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of non-cancer chronic pain.
Sandner-Kiesling A; Leyendecker P; Hopp M; Tarau L; Lejcko J; Meissner W; Sevcik P; Hakl M; Hrib R; Uhl R; Dürr H; Reimer K
Int J Clin Pract; 2010 May; 64(6):763-74. PubMed ID: 20370845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
